AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03161288
Drug: KY1005
RxNorm normalized name: Immunoglobulin g4 (235-proline,242-glutamic acid), anti-(human ox40 ligand) (human monoclonal ky1005-2d10 .gamma.4-chain), disulfide with human monoclonal ky1005-2d10 .kappa.-chain, dimer
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A human anti-OX40 ligand monoclonal antibody
Trial: NCT01826851
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU.
Trial: NCT00478465
Drug: valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01817283
Drug: Triptolide
RxNorm normalized name: Triptolide
DrugBank: Triptolide (DB12025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
Trial: NCT01817283
Drug: cART
RxNorm normalized name: CARTON
DrugBank: Carteolol (DB00521)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
Trial: NCT00622284
Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg
RxNorm normalized name: edaravone
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo tablets once daily
Trial: NCT00622284
Drug: BI 1356
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg, once daily in the morning for 104 weeks
Trial: NCT00622284
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
Trial: NCT01717287
Drug: Raltegravir Film-coated Tablet
RxNorm normalized name: raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01717287
Drug: Raltegravir Chewable Tablet
RxNorm normalized name: raltegravir Chewable Tablet
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02425579
Drug: Inhaled Carbon Monoxide at 100ppm (4 participants)
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
Trial: NCT02425579
Drug: Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Medical Air for up to 90 minutes daily for 5 days
Trial: NCT02425579
Drug: Inhaled Carbon Monoxide at 200ppm (4 participants)
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
Trial: NCT02425579
Drug: Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)
RxNorm normalized name: carbon monoxide
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Medical Air for up to 90 minutes daily for 5 days
Trial: NCT02242201
Drug: PNB Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT02242201
Drug: PAI Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT02242201
Drug: PAI liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT04200417
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
Trial: NCT04200417
Drug: Lipiodol
RxNorm normalized name: Lipiodol
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin (5mg/m\^2,maximum mitomycin dose 20 mg) will be dissolved in lipiodol at 2 mg/ml on the day of procedure.
Trial: NCT03262688
Drug: Bupivacaine HCl collagen-matrix implant
RxNorm normalized name: Matrix
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placement of the bupivacaine collagen-matrix in the surgical site
Trial: NCT03262688
Drug: Bupivacaine HCl infiltration
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infiltration of the surgical site
Trial: NCT00556127
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 on day 1
Trial: NCT00556127
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 110 mg/m2 on day 3
Trial: NCT00556127
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 (maximum 2 mg) on day 3
Trial: NCT00556127
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 from day 1 to 5
Trial: NCT00556127
Drug: Granulocyte-colony-stimulating factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (G-CSF 5 μg/Kg/day) from day 5 to day 11
Trial: NCT00282984
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg twice daily by mouth for 12 weeks
Trial: NCT01587378
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
Trial: NCT00651352
Drug: 4 mg nicotine lozenge
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: marketed formulation
Trial: NCT00556127
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg/m2 for 3-day
Trial: NCT00556127
Drug: Cytarabine ARA-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 g/m2/12 hours for six doses in 3-hour infusion
Trial: NCT00556127
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg/m2/12 hours before ARA-C administration
Trial: NCT00556127
Drug: Carmustine BCNU
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/m2 on day -7
Trial: NCT00556127
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m2/12 hours
Trial: NCT00556127
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140 mg/m2 on day -2
Trial: NCT02982590
Drug: Apixaban 5 MG Oral Tablet [ELIQUIS]
RxNorm normalized name: apixaban 5 MG Oral Tablet [Eliquis]
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
Trial: NCT04291066
Drug: N-Acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
Trial: NCT02982590
Drug: Warfarin Sodium
RxNorm normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: as controlled arm since warfarin is the standard therapy for LV thrombus
Trial: NCT00785044
Drug: I-123 mIBG
RxNorm normalized name: I 123
DrugBank: Iodide I-123 (DB09420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This was an observational study. Participants were previously dosed in separate study.
Trial: NCT00087347
Drug: ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00651352
Drug: 2 mg nicotine lozenge
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: marketed formulation
Trial: NCT00651352
Drug: 2 mg nicotine prototype
RxNorm normalized name: nicotine 2 MG
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg
Trial: NCT00651352
Drug: 4 mg nicotine prototype
RxNorm normalized name: nicotine 4 MG
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg
Trial: NCT00190671
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
Trial: NCT00190671
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
Trial: NCT02577926
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
Trial: NCT02577926
Drug: BAT
RxNorm normalized name: RibaTab
DrugBank: Equine Botulinum Neurotoxin E Immune FAB2 (DB13897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
Trial: NCT00268632
Drug: risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01402947
Drug: Ciprofloxacin XR + MMX Placebo
RxNorm normalized name: ciprofloxacin Extended Release Oral Tablet
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
Trial: NCT01402947
Drug: MMX Mesalazine/mesalamine + Ciprofloxacin XR
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
Trial: NCT00916942
Drug: capsaicin 8%
RxNorm normalized name: CAPSAICIN 8% PATCH KIT,4
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High concentration capsaicin 8% dermal patch applied for one hour
Trial: NCT00916942
Drug: Lidocaine (2.5%)/Prilocaine (2.5%) Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-treatment for NGX-4010
Trial: NCT03926130
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03926130
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03926130
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT03926130
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT03583333
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label 600 mg Linezolid
Trial: NCT03220867
Drug: Risperidone: Gurabo Risperdal (reference)
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive 1\*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
Trial: NCT00591630
Drug: Zevalin
RxNorm normalized name: Zevalin KIT
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
Trial: NCT00591630
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/m\^2 by vein.
Trial: NCT00591630
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 by vein every 12 hours.
Trial: NCT00591630
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 by vein every 12 hours.
Trial: NCT00591630
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 140 mg/m\^2 by vein.
Trial: NCT00591630
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm 1, Arm 2 = 250 mg/m\^2 by vein;~Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m\^2 by vein following Stem Cell Transplant;~Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy.
Trial: NCT01513070
Drug: Isosorbide Dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide Dinitrate，10mg，tid，po. for six months
Trial: NCT01513070
Drug: Placebo of Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
Trial: NCT01513070
Drug: Aspirin Enteric-coated Tablets
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
Trial: NCT00229645
Drug: Quetiapine Fumarate (Seroquel®)
RxNorm normalized name: quetiapine Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01223612
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
Trial: NCT01492894
Drug: Cyclosporins/Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
Trial: NCT01492894
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Change from current calcineurin inhibitor to Sirolumus
Trial: NCT01187966
Drug: Safinamide
RxNorm normalized name: Safinamide
DrugBank: Safinamide (DB06654)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02848326
Drug: Atogepant
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atogepant capsule.
Trial: NCT02848326
Drug: Placebo-matching Atogepant
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo-matching atogepant capsule.
Trial: NCT01636570
Drug: Vitamin D3 (cholecalciferol)
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
Trial: NCT00516048
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Trial: NCT00362414
Drug: Dual Growth Factor
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation
Trial: NCT00215995
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As outlined in Detailed Description
Trial: NCT00215995
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As outlined in Detailed Description
Trial: NCT00215995
Drug: ZD 1839
RxNorm normalized name: ZD-6126
DrugBank: ZD-6126 (DB11872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As outlined in Detailed Description
Trial: NCT00333671
Drug: Glycerol
RxNorm normalized name: Glycerol
DrugBank: Glycerin (DB09462)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00162864
Drug: montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00307645
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00090857
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02097524
Drug: Sarilumab
RxNorm normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02097524
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00820911
Drug: cyclosporine (reduced exposure) / everolimus
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT00820911
Drug: AEB071 300 mg b.i.d. / everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: twice daily
Trial: NCT00820911
Drug: AEB071 200 mg b.i.d. / everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: twice daily
Trial: NCT02538016
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01347424
Drug: Paclitaxel , carboplatin, endostatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3-4h， d1～15，q3w
Trial: NCT01347424
Drug: Paclitaxel and Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
Trial: NCT00590395
Drug: 18FDG (an FDA-approved radiopharmaceutical)
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
Trial: NCT03649048
Drug: High-Dose Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of High-Dose Cisplatin
Trial: NCT03649048
Drug: Low-Dose Cisplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Low-Dose Cisplatin
Trial: NCT02486822
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
Trial: NCT00307645
Drug: Prednisone (and methylprednisolone)
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01738542
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
Trial: NCT03252938
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab i.v.
Trial: NCT04686786
Drug: CVL-865
RxNorm normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
Trial: NCT04436640
Drug: Bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive bimekizumab at prespecified time-points.
Trial: NCT01738542
Drug: Statins
RxNorm normalized name: Endostatins
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01244126
Drug: morphine IM
RxNorm normalized name: LAPINE MORPHINE IMMUNE GLOBULIN
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg morphine IM for postop pain
Trial: NCT01244126
Drug: IV morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg morphine IV
Trial: NCT01101438
Drug: metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT00304447
Drug: Mylotarg
RxNorm normalized name: Mylotarg
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no